Navigation Links
AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Jun 8, 2007 - AVANIR Pharmaceuticals (NASDAQ:AVNR) today announced the presentation of Phase III data, including efficacy, safety and improvements in patient-centered outcomes in patients with diabetic peripheral neuropathic (DPN) pain treated with the investigational drug Zenvia(TM) (dextromethorphan/quinidine (DM/Q)), an NMDA receptor antagonist and sigma-1 agonist. The data were accepted as 'late-breakers' and presented in two posters at the Second International Congress on Neuropathic Pain (ICNP) in Berlin.

DPN pain is a common complication of diabetes that has significant impact on outcomes of concern to patients including sleep, activity and quality of life. In a multi-center, 3-month, double-blind Phase III trial, active treatment with Zenvia 45/30 mg dosed twice daily (DM/Q 45) and 30/30 mg DM/Q dosed twice daily (DM/Q 30) over a three month period, was compared to placebo. AVANIR previously announced in April 2007 that both doses of Zenvia had met the primary endpoint of statistically significant improvements versus placebo as recorded in daily patient diary entries using the Pain Rating Scale, as defined in the Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). In addition the DM/Q 45 met statistical significance for 4 out of 5 secondary endpoints reported.

Highlights of new Zenvia data presented at ICNP:

-- DM/Q 45 achieved 53%, 59% and 59% improvement versus baseline, DM/Q 30 achieved 43%, 48% and 48% improvement and placebo achieved 27%, 34% and 39% improvement at days 30, 60 and 90, respectively in the Pain Rating Scale.

-- 28% of patients in the DM/Q 45 arm and 27% in the DM/Q 30 arm obtained "a lot" of or "complete" pain relief at three months versus 17% in the placebo group (p=0.0008 and p=0.0017 respectively)

-- Active treatment with both Zenvia doses significantly reduced pain interference with
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at Second International Congress on Neuropathic Pain
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:7/30/2014)... , July 30, 2014  El Camino Hospital, a ... care, is utilizing the Leaf Patient Monitoring system to ... and movement of patients susceptible to bed sores. ... month-long, 138-patient study of the system, which showed dramatic ... Turning patients regularly is the one of the most ...
(Date:7/30/2014)... July 30, 2014  InnoPharma, Inc. today announced the ... generic equivalent of Zyprexa® injection), in Canada.  Olanzapine is ... behaviors in patients with schizophrenia or bipolar I mania. ... drug, InnoPharma has entered into an agreement with Sandoz ... will make, use, sell, market and distribute Olanzapine Injection ...
(Date:7/30/2014)... 30, 2014 Cynosure, Inc. (NASDAQ: ... treatments for non-invasive and minimally invasive applications, today announced that ... Operating Officer and Chief Financial Officer Timothy W. Baker ... Baker, 53, will continue to serve as CFO and will ... who remains Chairman and Chief Executive Officer. ...
Breaking Medicine Technology:El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2
(Date:7/30/2014)... revitalized and expanded through a U.S.-funded effort that ... access and providing cutting-edge skills labs and other ... by participants of the $130 million Medical Education ... progress being made at the African institutions. Their ... by the journal Academic Medicine . Begun ...
(Date:7/30/2014)... HealthDay Reporter WEDNESDAY, July 30, 2014 ... least 2,000 Americans die from extreme heat or cold, floods ... stroke or sun stroke caused nearly one-third of more than ... the U.S. Centers for Disease Control and Prevention. Cold ... -- accounted for 63 percent of those weather-related deaths. The ...
(Date:7/30/2014)... SF Cable, distributor of the highest quality cables, ... internet with guaranteed customer satisfaction announces the availability of ... These lightning cords are MFI certified to meet Apple ... Cable Lightning to USB Cables feature the ... and syncing. Compatible with the iPhone 5S/5C/5 plus iPad ...
(Date:7/30/2014)... 30, 2014 Visitors to our region ... $8,500 to ensure its protection. Bob Kiesendahl, one of ... to the Delaware Highlands Conservancy for donations collected through ... $2-per-stay donations add up fast, as visitors welcome the ... Delaware River Region. , The Kiesendahl family has owned ...
(Date:7/30/2014)... DRE Medical — a leading medical equipment ... its Medical Trade Shows & Conventions Calendar Schedule ... equipment vendors. , The calendar is a continually-updating guide ... States and around the world. Hundreds of entries are ... always growing. , Information listed on each trade show ...
Breaking Medicine News(10 mins):Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 3Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2
... Ensign Group, Inc. (Nasdaq: ENSG ), the parent company of the Ensign™ ... that its Board of Directors has declared a quarterly cash dividend of ... April 30, 2010 to shareholders of record as of March 31, ... ...
... March 15 Centocor Ortho Biotech Products has informed PharmaMar SA (Grupo Zeltia, ... have approved Yondelis(R) for advanced soft tissue sarcoma (STS) in adults. Furthermore, the authorities ... ovarian cancer (ROC). Yondelis is already approved for STS in Paraguay and ... ...
... Spotlighting the importance of oral health care for expectant mothers, the California Dental Association (CDA) Foundation has released new guidelines designed to emphasize the safety of dental treatment during ... ... ... ...
... at the University of Minnesota Medical School have discovered ... the hearts of Duchenne muscular dystrophy patients a ... children. The chemical, which Medical School scientists have termed ... heart muscle. When injected into the bloodstream, the molecular ...
... aspects of March Madness, offer tips to temper drawbacks , ... , , ... ... CHICAGO , March 15 ...
... ON , March 15 /PRNewswire-FirstCall/ - Nuvo Research ... the research and development of drug products that are delivered ... drug delivery technologies, and on the development of its immune ... the first patient in its European Phase 2 clinical trial ...
Cached Medicine News:Health News:The Ensign Group Declares Quarterly Dividend 2Health News:Yondelis(R) Receives Five New Approvals Outside the European Economic Area 2Health News:Yondelis(R) Receives Five New Approvals Outside the European Economic Area 3Health News:Yondelis(R) Receives Five New Approvals Outside the European Economic Area 4Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 2Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 3Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 4Health News:Researchers discover chemical that may protect hearts of muscular dystrophy patients 2Health News:Experts Say It's Not So Bad to Go a Little Mad 2Health News:Experts Say It's Not So Bad to Go a Little Mad 3Health News:Experts Say It's Not So Bad to Go a Little Mad 4Health News:Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial 2Health News:Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial 3Health News:Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial 4Health News:Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial 5
Lyphochek Coagulation Control is a human plasma control for monitoring the performance of routine coagulation tests. It has an extended reconstituted stability which helps reduce waste and save money...
Lyphochek® Hemoglobin A1C Linearity Set is a human whole blood based product designed to verify linearity throughout the patient reportable range of hemoglobin A1C assays....
... Hematology-16 Control is specifically ... most hematology analyzers that ... parameters and 3-part white ... trilevel control can be ...
Each Liquichek Seroconversion Panel features a series of serum specimens drawn over time from one individual to show the progression from a negative to a positive disease state....
Medicine Products: